A Randomized, Active-comparator Controlled, Parallel-group Study, to Evaluate the Effect of Empagliflozin and Dulaglutide on MAFLD in Patients With Type 2 Diabetes Mellitus
Latest Information Update: 06 Oct 2022
At a glance
- Drugs Dulaglutide (Primary) ; Empagliflozin (Primary)
- Indications Type 2 diabetes mellitus
- Focus Therapeutic Use
- 01 Oct 2022 Planned initiation date changed from 1 Mar 2022 to 1 Dec 2023.
- 05 Jan 2022 Planned number of patients changed from 156 to 135.
- 03 Dec 2021 New trial record